#United States #Dividend #Minneapolis #Bio-Techne #Merck KGaA

Bio-Techne Corporation Declares Dividend

Bio-Techne Corporation (NASDAQ: TECH), a leading company in the life sciences sector, has made an important announcement for its investors and stakeholders. On November 3, 2026, the company disclosed that its Board of Directors has resolved to distribute a dividend of $0.08 per share for the quarter ending September 30, 2026. The dividend is scheduled to be paid out on November 23, 2026, to all shareholders of record as of the close of business on November 13, 2026.

The declaration comes at a crucial time as Bio-Techne is also navigating a significant transaction with Merck KGaA, Darmstadt, Germany. This potential acquisition places additional scrutiny on the dividend payment, as it is contingent upon whether the acquisition has been finalized before the dividend record date.

Despite the uncertainties surrounding this merger, the dividend announcement underscores Bio-Techne's commitment to its shareholders and reinforces confidence in its financial health. The company has experienced substantial growth, with reported net sales exceeding $1.2 billion in the fiscal year 2026, further solidifying its position in the market. With a dedicated workforce of approximately 3,000 employees worldwide, Bio-Techne remains at the forefront of innovation within the life sciences sector.

Bio-Techne offers a variety of biomedical tools and bioactive reagents that are designed for the research and clinical diagnostics communities. Its products are integral to scientific investigations, aiding researchers in the exploration of biological processes and contributing to a deeper understanding of various diseases. The tools provided by Bio-Techne are essential in supporting drug discovery initiatives and in facilitating accurate clinical tests and diagnoses.

The Board of Directors has announced that they will evaluate future cash dividends on a quarterly basis, which indicates a proactive approach in managing shareholder returns amid a dynamic business environment. Investors will be closely watching how the proposed transaction with Merck KGaA unfolds, as it will play a pivotal role in shaping the future of Bio-Techne.

In light of this development, it is crucial for shareholders to stay informed regarding the pending acquisition and its implications for Bio-Techne’s operational strategies and dividend policy. As the company moves forward, it remains focused on delivering value to both its customers and shareholders, promising a sustainable growth trajectory in the face of evolving industry demands. For additional information and updates regarding Bio-Techne's dividend payments and other corporate activities, please refer to their official website at www.bio­techne.com.

As always, potential investors and stakeholders are encouraged to review the company's Annual Report on Form 10-K and other regulatory filings to understand the various risk factors affecting Bio-Techne. The management is committed to keeping the public apprised of any changes to its corporate strategy as they navigate through these complex scenarios, ensuring transparency and trust within its investor community.

In conclusion, Bio-Techne's declaration of a quarterly dividend affirmatively illustrates its robust business model and dedication to its shareholders. As the company continues to innovate and expand its global reach, it promises to remain a vital player in the life sciences domain, with exciting developments ahead.

For questions or comments regarding this dividend announcement, investors may reach out to David Clair, Vice President of Investor Relations, at 612-656-4416 or via email at the provided contact channel.

Stay tuned for further updates on this story as it develops, particularly regarding the pending acquisition and its potential effects on Bio-Techne's operations and shareholder communications.